Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARMP Armata Pharmaceuticals	$1.35 -3.6%	$1.44	$0.90 ▼ $3.42	$48.84M	0.87	11,411 shs	4,814 shs
CTMX CytomX Therapeutics	$2.03 +1.5%	$0.82	$0.40 ▼ $2.55	$163.66M	1.11	2.06 million shs	5.85 million shs
DSGN Design Therapeutics	$3.51 +4.5%	$3.88	$2.60 ▼ $7.77	$199.26M	1.77	187,548 shs	70,352 shs
OCGN Ocugen	$0.76 +6.9%	$0.67	$0.52 ▼ $1.98	$221.47M	4.21	4.44 million shs	8.33 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARMP Armata Pharmaceuticals	0.00%	+4.65%	+9.76%	-63.11%	-63.11%
CTMX CytomX Therapeutics	0.00%	+118.66%	+209.45%	+154.93%	+3.57%
DSGN Design Therapeutics	0.00%	+0.57%	+0.29%	-13.97%	-22.17%
OCGN Ocugen	0.00%	+13.11%	+11.63%	+5.64%	-61.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARMP Armata Pharmaceuticals	1.7684 of 5 stars	3.5	3.0	0.0	0.9	1.7	0.0
CTMX CytomX Therapeutics	4.3058 of 5 stars	3.5	1.0	4.7	3.0	2.5	1.3
DSGN Design Therapeutics	0.7914 of 5 stars	2.0	0.0	0.0	1.7	2.5	0.6
OCGN Ocugen	1.1622 of 5 stars	3.5	1.0	0.0	2.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARMP Armata Pharmaceuticals	3.00	Buy	$7.00	418.52% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.33	162.73% Upside
DSGN Design Therapeutics	2.00	Hold	$4.00	13.96% Upside
OCGN Ocugen	3.00	Buy	$6.00	691.14% Upside

Current Analyst Ratings Breakdown

Latest ARMP, OCGN, DSGN, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
5/12/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
5/12/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50
3/7/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00
3/7/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/6/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$6.00 ➝ $7.00
3/6/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00

(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARMP Armata Pharmaceuticals	$4.53M	10.78	N/A	N/A	($0.89) per share	-1.52
CTMX CytomX Therapeutics	$147.56M	1.11	N/A	N/A	($0.71) per share	-2.86
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$4.96 per share	N/A
OCGN Ocugen	$4.52M	48.98	N/A	N/A	$0.16 per share	4.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARMP Armata Pharmaceuticals	-$69.04M	-$1.64	N/A	N/A	N/A	N/A	N/A	-60.91%	5/20/2025 (Estimated)
CTMX CytomX Therapeutics	-$570K	$0.48	11.94	N/A	N/A	10.96%	-41.47%	8.11%	N/A
DSGN Design Therapeutics	-$66.86M	-$0.99	N/A	N/A	N/A	N/A	-18.01%	-17.38%	8/4/2025 (Estimated)
OCGN Ocugen	-$63.08M	-$0.19	N/A	N/A	N/A	-532.51%	-154.75%	-90.79%	N/A

Latest ARMP, OCGN, DSGN, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	DSGN Design Therapeutics	-$0.28	-$0.31	-$0.03	-$0.31	N/A	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
5/9/2025	Q1 2025	OCGN Ocugen	-$0.06	-$0.05	+$0.01	-$0.05	N/A	$1.48 million
3/10/2025	Q4 2024	DSGN Design Therapeutics	-$0.28	-$0.24	+$0.04	-$0.24	N/A	N/A
3/6/2025	Q4 2024	CTMX CytomX Therapeutics	-$0.23	$0.22	+$0.45	$0.22	$13.53 million	$38.09 million
3/5/2025	Q4 2024	OCGN Ocugen	-$0.05	-$0.05	N/A	-$0.05	$0.30 million	$0.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARMP Armata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARMP Armata Pharmaceuticals	N/A	0.19	0.19
CTMX CytomX Therapeutics	N/A	1.04	1.04
DSGN Design Therapeutics	N/A	34.61	34.61
OCGN Ocugen	0.04	2.58	2.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARMP Armata Pharmaceuticals	3.57%
CTMX CytomX Therapeutics	67.77%
DSGN Design Therapeutics	56.64%
OCGN Ocugen	10.27%

Insider Ownership

Company	Insider Ownership
ARMP Armata Pharmaceuticals	85.50%
CTMX CytomX Therapeutics	7.00%
DSGN Design Therapeutics	31.20%
OCGN Ocugen	4.29%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARMP Armata Pharmaceuticals	70	36.18 million	5.25 million	Not Optionable
CTMX CytomX Therapeutics	170	80.62 million	72.78 million	Optionable
DSGN Design Therapeutics	40	56.77 million	38.96 million	Optionable
OCGN Ocugen	80	292.03 million	278.82 million	Optionable

ARMP, OCGN, DSGN, and CTMX Headlines

Recent News About These Companies

Noble Financial Predicts Ocugen's Q2 Earnings (NASDAQ:OCGN)

May 16 at 6:03 AM | marketbeat.com

Noble Financial Issues Positive Forecast for Ocugen Earnings

May 16 at 2:39 AM | americanbankingnews.com

The Analyst Verdict: Ocugen In The Eyes Of 5 Experts

May 14, 2025 | nasdaq.com

Ocugen (NASDAQ:OCGN) Price Target Cut to $7.00 by Analysts at HC Wainwright

May 14, 2025 | marketbeat.com

Ocugen's (OCGN) "Buy" Rating Reiterated at Chardan Capital

May 14, 2025 | marketbeat.com

HC Wainwright Has Lowered Expectations for Ocugen (NASDAQ:OCGN) Stock Price

May 14, 2025 | americanbankingnews.com

Ocugen (NASDAQ:OCGN) Releases Earnings Results, Beats Estimates By $0.01 EPS

May 13, 2025 | marketbeat.com

Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy

May 13, 2025 | msn.com

1OCGN : The Analyst Verdict: Ocugen In The Eyes Of 5 Experts

May 13, 2025 | benzinga.com

Ocugen, Inc. (NASDAQ:OCGN) Q1 2025 Earnings Call Transcript

May 10, 2025 | msn.com

Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish

May 9, 2025 | msn.com

Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 9, 2025 | globenewswire.com

A Look at Ocugen's Upcoming Earnings Report

May 9, 2025 | benzinga.com

Ocugen (OCGN) Projected to Post Earnings on Friday

May 6, 2025 | marketbeat.com

Ocugen to Host Q1 2025 Earnings Call and Business Update on May 9

May 5, 2025 | msn.com

OCUGEN Earnings Preview: Recent $OCGN Insider Trading, Hedge Fund Activity, and More

May 2, 2025 | nasdaq.com

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

May 2, 2025 | globenewswire.com

Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences

May 2, 2025 | msn.com

Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences

May 2, 2025 | msn.com

Ocugen to Present at Eyecelerator Conference May 2025

May 1, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARMP, OCGN, DSGN, and CTMX Company Descriptions

Armata Pharmaceuticals NYSEAMERICAN:ARMP

$1.35 -0.05 (-3.57%)

As of 05/16/2025 04:10 PM Eastern

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

CytomX Therapeutics NASDAQ:CTMX

$2.03 +0.03 (+1.50%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$2.05 +0.02 (+1.18%)

As of 05/16/2025 07:52 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Design Therapeutics NASDAQ:DSGN

$3.51 +0.15 (+4.46%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$3.51 0.00 (0.00%)

As of 05/16/2025 04:05 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Ocugen NASDAQ:OCGN

$0.76 +0.05 (+6.92%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$0.75 -0.01 (-1.11%)

As of 05/16/2025 07:46 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time